[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Siriraj Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":555},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,41,71,99,127,153,178,197,218,244,282,308,332,359,389,413,434,461,484,510,533],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100534471","validity-and-reliability-of-thai-version-clinical-questionnaire-for-diagnosis-of-carpal-tunnel-syndrome-100534471",false,"NCT06239259","Validity and Reliability of Thai Version Clinical Questionnaire for Diagnosis of Carpal Tunnel Syndrome","Validity and Reliability of Thai Version of Kamath and Stothard Clinical Questionnaire for Diagnosis of Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Patients aged 18 years and older who are admitted to Siriraj Hospital with signs and symptoms consistent with carpal tunnel disease.\n* Diagnosis of carpal tunnel disease was confirm with electrodiagnostic study and electromyography\n* Must be able to communicate in Thai.\n\nExclusion Criteria:\n\n* Patients diagnosed with other neurological diseases such as cerebrovascular disease, cervical radiculopathy, diabetic neuropathy, tumors of the nerve endings in the arm, and other peripheral neuropathy.\n* Pregnancy or breastfeeding\n* History of recieving chemotheraphy agent\n* Patient who recieved surgical treatment for carpal tunnel syndrome.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","OBSERVATIONAL","The Kamath and Stothard clinical questionnaire for diagnosing carpal tunnel syndrome (CTS) is a valid score for diagnosis of CTS. However it haven't been translated in to Thai version and the validity and accuracy of the Thai the Thai version have not been yet verified.\n\nThe research team recognizes the importance and potential benefits of adapting this assessment for use within the Thai population.Therefore, we aim to conduct this research to translate the questionnaire from the original English to Thai and to assess its validity and reliability for diagnosing patients with Carpal Tunnel Syndrome.",[24],"Carpal Tunnel Syndrome",[24,26,27],"Diagnosis","Content validity","RECRUITING","2026-05-18",{"date":31,"type":32},"2026-05-20","ACTUAL",{"date":34,"type":32},"2023-07-06",{"date":36,"type":20},"2026-12-31",{"name":38,"class":39},"Siriraj Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":40},"100638020","postoperative-hypofractionated-whole-pelvic-radiotherapy-in-cervical-and-endometrial-cancer-100638020","NCT07595224","Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer","PostOPerative HYPOfractionated Whole Pelvic Radiotherapy in Cervical (Cx) and Endometrial Cancer (PostOP HYPOCxE Trial) : A Phase II Non-inferiority Randomized Controlled Trial","PostOP HYPOCxE","Inclusion Criteria:\n\n1. Pathologically proven carcinoma of the uterine cervix; and carcinoma and carcinosarcoma of uterine corpus\n2. Hysterectomy (total abdominal hysterectomy, vaginal hysterectomy, total laparoscopic hysterectomy or radical hysterectomy) for cancer of the cervix or endometrium within 49 days prior to registration. Hence inadvertent surgery will be allowed for inclusion.\n3. Indicated for adjuvant EBRT from multidisciplinary team discussion.\n4. Non-metastatic stage according to FIGO 2018 for Cervical cancer and FIGO 2023 for Endometrial cancer and TNM guidelines from appropriate diagnostic workup 4.1 History\u002Fphysical examination within 45 days prior to registration 4.2 CT\u002FMRI\u002FPET-CT of abdomen\u002Fpelvis demonstrating the absence of distant metastasis, performed pre- or post-surgery within 90 days prior to registration 4.3 Chest x-ray or chest CT (or a PET\u002FCT) performed within 90 days prior to registration\n5. Age ≥18 years old with informed consent\n\nExclusion Criteria:\n\n1. Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin\n2. Small cell neuroendocrine cancer, melanoma, uterine sarcoma, and other rare cancers in the cervix and uterus\n3. Metastatic disease beyond intervertebral disc L2\u002F3 level\n4. Previous pelvic or abdominal radiotherapy\n5. Combination of preoperative chemotherapy or radiotherapy with surgery\n6. Contra-indications to EBRT",{"count":50,"type":20},120,"INTERVENTIONAL",[53],"NA","This study aims to evaluate a shorter course of postoperative pelvic radiotherapy in patients with cervical and endometrial cancer. The standard radiotherapy schedule usually requires many treatment sessions over several weeks, which can be burdensome for patients and may affect their ability to complete treatment.\n\nThis study will compare a shorter radiotherapy schedule (hypofractionated radiotherapy) with the standard schedule. Both treatments deliver a similar total radiation dose, but the shorter schedule reduces the number of hospital visits and overall treatment time.\n\nParticipants will be randomly assigned to receive either the shorter or standard radiotherapy after surgery. The study will evaluate side effects, treatment effectiveness, and quality of life. The goal is to determine whether the shorter treatment is as safe and effective as the standard approach.",[56,57],"Endometrial Cancer","Cervix Cancer",[59,56,60,61,62],"Cervical Cancer","Hypofractionated Radiotherapy","Whole Pelvic Radiotherapy","Postoperative Radiotherapy","2026-05-12",{"date":65,"type":32},"2026-05-19",{"date":67,"type":32},"2026-03-11",{"date":69,"type":20},"2028-12-31",{"name":38,"class":39},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100628077","prehabilitation-to-enhance-preoperative-function-in-elderly-undergoing-abdominal-malignancy-surgery-100628077","NCT07456943","Prehabilitation to Enhance Preoperative Function in Elderly Undergoing Abdominal Malignancy Surgery","Prehabilitation to Enhance Preoperative Function in Elderly Undergoing Abdominal Malignancy Surgery: A Prospective Study at Siriraj Hospital","Inclusion Criteria:\n\n* Diagnosed with intraabdominal malignancy (e.g., colorectal, esophageal, gastric, pancreatic, hepatic, biliary tract, urinary bladder, or endometrial malignancies).\n* Schedules for elective major surgery and formally enrollment in the ERAS program at Siriraj Hospital. (at Siriraj Hospital, patients scheduled for pre-specific elective major surgeries are enrolled into the ERAS program as individual hospital protocols for each ERAS module. All patients are informed about the ERAS program by their surgical team.)\n* Referred to the SiPAP center for prehabilitation in accordance with the ERAS preoperative protocol, with a minimum preoperative time of 14 days before the scheduled surgery date.\n* Able to understand the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n* Have emergency surgery\n* Reschedule the surgery for an earlier date, allowing less than 14 days for prehabilitation.\n* Severe cardiopulmonary or musculoskeletal conditions that contraindicate exercise (e.g., unstable angina, decompensated heart failure, severe COPD, or orthopedic disability).\n* Cognitive impairment or psychiatric illness precluding participation in prehabilitation.\n* Refusal to participate.\n* Inability to comply with the protocol.","60 Years","90 Years",{"count":81,"type":20},110,"The goal of this observational study is to evaluate the effectiveness of the multimodal prehabilitation program at the Siriraj Integrated Preoperative and Prehabilitation Center (SiPAP) on improving preoperative walking capacity and functional status in patients undergoing elective intraabdominal cancer surgery. The main question it aims to answer is:\n\n\\- Does the prehabilitation program lead to a significant change in 6-minute walk distance (6MWD) at preoperative admission as compared to at baseline assessment? Participants will receive the structured multimodal prehabilitation program, which represents the standard of care for patients in the ERAS protocol at the study site. Outcomes will be measured at preoperative admission and at 1 and 3 months after surgery.",[84,85],"Prehabilitation","Functional Capacity",[84,87,88,89],"Functional capacity","Preoperative care","Abdominal cancer surgery","NOT_YET_RECRUITING","2026-04-22",{"date":93,"type":32},"2026-04-28",{"date":95,"type":20},"2026-05",{"date":97,"type":20},"2027-12",{"name":38,"class":39},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":51,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100619329","early-norepinephrine-administration-and-rapid-dose-adjustment-100619329","NCT07343206","Early Norepinephrine Administration and Rapid Dose Adjustment","Efficacy of Early Norepinephrine Administration and Rapid Dose Adjustment in Adult Septic Shock Patients: A Multicenter Randomized Controlled Trial","CENSER2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Sepsis: SOFA ≥2 with suspected infection\n* Mean arterial pressure \\\u003C65 mmHg\n* Diagnosed within 3 hours\n\nExclusion Criteria:\n\n* Do-not-resuscitate orders\n* Pregnancy\n* Severe concurrent conditions (acute stroke, acute coronary syndrome, acute pulmonary edema, status asthmaticus, active gastrointestinal bleeding, status epilepticus, severe burn, severe trauma, and fatal drug overdose, End-stage malignancy\n* Peripheral arterial disease\n* Prior norepinephrine administration\n* Recurrent shock in the same patient",{"count":108,"type":20},600,[53],"The goal of this clinical trial is to determine whether early initiation of norepinephrine with rapid dose adjustment improves clinical outcomes in adult patients with septic shock. The study aims to evaluate the effect of early norepinephrine administration on mortality, hemodynamic stabilization, and resuscitation efficiency in adults aged 18 years and older diagnosed with septic shock.\n\nThe main questions it aims to answer are:\n\n* Does early norepinephrine administration with rapid dose titration reduce 28-day mortality compared with standard treatment?\n* Does early norepinephrine administration with rapid dose tiration lead to faster shock control and reduced fluid requirements without increasing treatment-related adverse events?\n\nResearchers will compare early norepinephrine administration with rapid dose adjustment to placebo with standard sequential resuscitation and rescue norepinephrine as needed to see if early vasopressor initiation improves survival, shock resolution, and safety outcomes.\n\nParticipants will:\n\n* Receive either norepinephrine or placebo infusion initiated within one hour of septic shock diagnosis, with dose adjustment every 15 minutes according to a standardized protocol\n* Undergo close hemodynamic and safety monitoring, including frequent vital sign assessment and limb perfusion evaluation\n* Receive standard sepsis care, including fluid resuscitation, antibiotics, and organ support as clinically indicated\n* Be followed for clinical outcomes and adverse events for up to 28 days after enrollment",[112,113],"Sepsis","Septic Shock",[115,116,117,118],"septic shock","norepinephrine","sepsis","hypotension","2026-04-21",{"date":91,"type":32},{"date":122,"type":32},"2026-01-01",{"date":124,"type":20},"2028-03",{"name":38,"class":39},6,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":51,"phases":136,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":40},"100611386","phase-2-resuscitation-enhancement-to-avoid-rearrest-through-evidence-based-strategies-in-prehospital-post-resuscitation-care-100611386","NCT07239908","Resuscitation Enhancement to Avoid Rearrest Through Evidence-based Strategies in Prehospital Post-resuscitation Care","RE-ARREST","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients with out-of-hospital cardiac arrest (OHCA) who received resuscitative care from the Siriraj Emergency Medical Services Center (SiEMS).\n\nPatients who achieved return of spontaneous circulation (ROSC) prior to hospital arrival.\n\n\\- Patients subsequently transported to the Emergency Department of Siriraj Hospital for further treatment.\n\nExclusion Criteria:\n\n* Suspected traumatic cardiac arrest.\n* ROSC patients whose legally authorized representative declined vasopressor administration, despite clinical indication according to the prehospital post-resuscitation care protocol.\n* ROSC patients who had not undergone endotracheal intubation, and whose legally authorized representative declined endotracheal intubation, despite protocol-based indication.\n* ROSC patients without rearrest whose legally authorized representative declined further blood investigations or additional procedures after arrival at the Emergency Department.\n* Patients whose legally authorized representative declined participation in the study.\n* Patients without an available legally authorized representative to provide consent for study participation.",{"count":135,"type":20},318,[137,138],"PHASE2","PHASE3","Out-of-hospital cardiac arrest (OHCA) remains a leading global emergency condition with low survival to hospital discharge despite advances in cardiopulmonary resuscitation. Return of spontaneous circulation (ROSC) rates have improved; however, 30-50% of patients experience rearrest after ROSC, which is associated with significantly reduced survival. Preventable physiologic factors related to prehospital care - including hypoxia, hypotension, and hyperventilation - are frequently identified prior to rearrest. Evidence-based post-ROSC clinical bundles exist mainly for in-hospital settings, while structured prehospital post-resuscitation care protocols are limited, particularly in resource-constrained environments.\n\nThe RE-ARREST project aims to develop, implement, and evaluate an evidence-based prehospital post-resuscitation care protocol designed for paramedic-led Emergency Medical Services. The intervention includes structured monitoring, tailored oxygenation and ventilation targets, vasopressor use criteria (norepinephrine), fluid management decision support, teamwork communication, and operational training workshops using simulation.\n\nThis is a quasi-experimental pre-post interventional study conducted at the Siriraj Emergency Medical Service (SiEMS), Thailand. The study compares outcomes from retrospective pre-implementation cases with prospective post-implementation cases, including both patient-centered outcomes and provider compliance. Adult OHCA patients with ROSC achieved prehospital and transported to Siriraj Hospital are eligible. The estimated sample size is 318 participants (pre-intervention 212; post-intervention 106) over two years.\n\nThe primary outcome is the incidence of rearrest within 1 hour after ROSC during prehospital care and initial emergency department management. Secondary outcomes include protocol compliance, survival-to-admission, and survival-to-hospital-discharge. The protocol emphasizes feasibility, safety, and replicability to inform scalable EMS clinical practice guidelines.\n\nThis research is expected to provide novel evidence on targeted prehospital post-ROSC care and has the potential to reduce rearrest, improve neurologically favorable survival, and strengthen EMS system quality improvement efforts in Thailand and other low-to-middle-resource settings.",[141],"Out-of-hospital Cardiac Arrest (OHCA)",[143,144,145],"Post cardiac arrest care","Out-of-hospital cardiac arrest","Prehospital care","2026-04-16",{"date":119,"type":32},{"date":149,"type":32},"2025-12-01",{"date":151,"type":20},"2028-12-01",{"name":38,"class":39},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":160,"targetDuration":162,"studyType":21,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":40},"100613088","the-impact-of-preoperative-nutrition-intervention-on-muscle-mass-preserve-in-older-adults-undergoing-elective-surgery-100613088","NCT07262034","The Impact of Preoperative Nutrition Intervention on Muscle Mass Preserve in Older Adults Undergoing Elective Surgery","The Impact of Preoperative Nutritional Intervention on Muscle Mass Preserve in Older Adult Undergoing Elective Surgery: A Prospective Cohort Study (SiPAP Trail) Study","Inclusion Criteria:\n\n1. Patients aged 60 years to 90 years\n2. Schedules for elective major surgery and formally enrollment in the Enhanced Recovery After Surgery (ERAS) program at Siriraj Hospital. (At Siriraj Hospital, patients scheduled for pre-specific elective major surgeries are enrolled into the ERAS program as individual hospital protocols for each ERAS module. All patients are informed about the ERAS program by their surgical team.)\n3. Referred to the SiPAP center for prehabilitation based on established ERAS hospital preoperative protocol.\n4. Able to provide written informed consent and willing to undergo all research assessments at both time points.\n\nExclusion Criteria:\n\n1. Presence of conditions that interfere with bioelectrical impedance analysis (BIA), including an implanted pacemaker or other non-removable electronic medical devices.\n2. Use of medications or supplements known to acutely or chronically affect muscle mass (e.g. corticosteroids, hormonal therapies) during the study period.\n3. Diagnosed neuromuscular disorders that affect baseline muscle mass and strength\n4. Undergo emergency surgery\n5. A planned interval of less than 14 days between the initial SiPAP visit and hospital admission for surgery.\n6. Alcohol consumption or strenuous exercise within the 12 hours preceding the scheduled BIA measurement.\n7. Incomplete data on muscle mass or nutritional assessment at either time point.",{"count":161,"type":20},62,"3 Months","Sarcopenia-the progressive loss of muscle mass and strength-is a major clinical issue, especially in surgical patients with malignancy. It's strongly linked to poor postoperative outcomes like increased complications, longer hospital stays, and higher mortality. Surgical stress (trauma, fasting, immobilization) significantly worsens this muscle catabolism.\n\nConsequently, early identification and targeted preoperative intervention are essential. Preoperative nutrition, part of a prehabilitation program, is a key strategy known to attenuate muscle loss and improve recovery. The Skeletal Muscle Index (SMI) is an objective metric used for risk stratification.\n\nThe Siriraj Integrated Preoperative and Prehabilitation Center (SiPAP) uses a multidisciplinary model with nutritional counseling, but lacks routine sarcopenia screening or objective SMI measurement. Therefore, the impact of their specific nutritional interventions on preserving muscle mass remains unevaluated.\n\nHypothesis: The structured, individualized preoperative nutritional intervention delivered by SiPAP to intraabdominal oncology patients will result in a net preservation or positive change in the Skeletal Muscle Index (SMI) over the preoperative period.",[165],"Nutrition Status",[167,168,169,170],"Preoperative","Sarcopenia","Body Composition Analyzer (BIA)","Skeletal Muscle Index (SMI)","2026-03-04",{"date":173,"type":32},"2026-03-06",{"date":175,"type":20},"2026-04-01",{"date":151,"type":20},{"name":38,"class":39},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":40},"100473634","guideline-adherence-for-preoperative-anemia-management-in-a-pac-100473634","NCT05447442","Guideline Adherence for Preoperative Anemia Management in a PAC","Adherence to the Hospital Guideline for Evaluation and Management of Preoperative Anemia in Preanesthesia Assessment Center (SIPAC), Siriraj Hospital","Inclusion Criteria Patients who attend a preanesthesia clinic and have anemia.\n\nAnemia defined as\n\n1. Patients, with chronic kidney disease (CKD) stage 3+ or hematologic disease, have a hemoglobin level less than 10 g\u002FdL; or\n2. Patients other than No. 1 and have hemoglobin level less than 13 g\u002FdL in men or a hemoglobin level less than 12 g\u002FdL in women.\n\nExclusion Criteria:\n\n* none",{"count":186,"type":20},93,"Anemia in surgical patients is a common seriously problem; around 40 % of patients presenting for major surgery are anemic problem. Patients with major surgery have significantly higher rates of acute blood loss. Whereas , patients with pre-operative anemia prone to be transfused blood component in pre-operative or intraoperative and postoperative periods that associated with worse outcomes , prolonged hospital stays , increased risk of morbidity and mortality . Therefore, patients undergoing major surgery should be optimization for pre-operative anemia.\n\nIn November 2021, Siriraj Preanesthesia Assessment Center (SIPAC) has developed and implemented a preoperative anemia management guideline which is one pillar of perioperative patient blood management. The objective of this guideline is to optimize red blood cell mass before patients having operation. The investigators are realize the important of pre-operative anemia of patients who undergoing elective surgery. The investigators will aim to evaluate adherence to the preoperative anemia management guideline protocol and perioperative outcomes and use the data of this study to setting guidelines for preoperative anemia evaluation and management in SIPAC of department of anesthesiology in Siriraj hospital for improving workflow and optimization before elective surgery, supporting to a reduction in blood transfusion, hospital stay, morbidity and health care costs of public health of Thailand.",[189,190],"Guideline Adherence","Anemia",{"date":173,"type":32},{"date":193,"type":32},"2022-10-01",{"date":195,"type":20},"2026-12",{"name":38,"class":39},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":40},"100602618","malnutrition-prevalence-and-nutritional-change-after-preoperative-nutrition-counseling-100602618","NCT07125859","Malnutrition Prevalence and Nutritional Change After Preoperative Nutrition Counseling","Prevalence of Preoperative Malnutrition and Changes in Nutritional Status Following Preoperative Nutrition Education in Surgical Patients Attending a Preoperative Clinic","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Enrolled in the Enhanced Recovery After Surgery (ERAS) program.\n3. Referred to the SiPAP program for prehabilitation prior to elective surgery.\n4. screened for malnutrition risk using the Society of Parenteral and Enteral Nutrition of Thailand (SPENT) screening tool.\n5. Complete clinical records available for analysis.\n\nExclusion Criteria: Have incomplete nutritional records.",{"count":108,"type":20},"Preoperative nutrition risk or Malnutrition is a prevalent up to 65% of surgical patients, leading to significant negative outcomes such as increased complications, poor wound healing, and higher healthcare costs. Preoperative nutrition status is a modifiable risk factor that can be optimized to improve surgical outcomes. Preoperative malnutrition screening creates an opportunity to identify and optimize the nutritional status of at-risk patients before surgery. This study is initiated to determine the prevalence of malnutrition among surgical patients enrolled in an Enhanced recovery after surgery (ERAS) program, using the SPENT and modified Nutrition Alert Form (NAF) during their visit to the preoperative clinic and evaluate the impact of preoperative nutrition education on body weight and nutrition status prior to surgery.",[165],[167,208,209],"Malnutrition","Nutrition education","2026-02-25",{"date":212,"type":32},"2026-02-27",{"date":214,"type":32},"2025-07-15",{"date":216,"type":20},"2026-07-01",{"name":38,"class":39},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":225,"sex":16,"minAge":17,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":51,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":40},"100601474","the-suggested-immobilization-test-with-exploratory-heart-rate-variability-analysis-for-diagnosis-of-restless-legs-syndrome-100601474","NCT07110961","The Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Diagnosis of Restless Legs Syndrome","Diagnostic Accuracy of the Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Restless Legs Syndrome in a Thai Population","Inclusion Criteria:\n\n* Patients who were appointed for an in-lab polysomnographic study and fit the clinical diagnosis criteria for restless leg syndrome based on International Restless Legs Syndrome Study Group (IRLSSG)\n\nExclusion Criteria:\n\n* Patient with physical limitations including stroke, dementia or hearing impairment\n* Pregnant women",true,"70 Years",{"count":228,"type":20},52,[53],"Restless leg syndrome (RLS) is not uncommon and can also affect people's health and quality of life. Mainly, RLS is diagnosed based on clinical criteria subjectively. Sometimes it is difficult to differentiate between RLS and mimickers, especially in patients with comorbidities such as diabetes or parkinson's disease. We believe that using objective tests would facilitate accuracy in RLS diagnosis, which leads to proper management of patients.",[232],"Restless Leg Syndrome",[234,235,236],"restless leg syndrome","sleep","suggested immobilization test","2026-02-10",{"date":239,"type":32},"2026-02-13",{"date":241,"type":32},"2025-10-01",{"date":36,"type":20},{"name":38,"class":39},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":225,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":51,"phases":254,"briefSummary":255,"conditions":256,"keywords":268,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":281},"100562499","prevention-of-edema-after-coronary-artery-bypass-graft-by-customized-pressure-guided-elastic-bandages-100562499","NCT06603961","Prevention of Edema After Coronary Artery Bypass Graft by Customized Pressure-guided Elastic Bandages","Efficacy of Customized Pressure-Guided Elastic Bandages in Preventing Postoperative Edema and Complications in Coronary Artery Bypass Graft (CABG) Patients: A Comparative Study of Compression Therapy and Standard Post-CABG Care.","PEACCE","Inclusion Criteria:\n\n1. All patients scheduled for elective coronary artery bypass grafting (CABG) surgery with saphenous vein harvesting from the leg at Siriraj Hospital.\n2. Patients aged 18 years and older undergoing CABG surgery with saphenous vein harvesting from the leg at Siriraj Hospital, who willingly consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with an Ankle-brachial pressure index (ABI) \\\u003C 0.8\n2. Patients with severe leg swelling (pitting edema of grade 3 or higher) or with pre-existing or post-operative heart failure that remains uncontrolled despite diuretic therapy.\n3. Patients with occlusive peripheral arterial disease (PAD) or chronic venous insufficiency (CEAP 2s), characterized by significant venous stasis, leg pain, varicose veins, or lymphadenopathy.",{"count":253,"type":20},106,[53],"The study aimed to assess the efficacy of customized pressure-guided elastic bandages (CPG-EB) in preventing postoperative edema and complications in Coronary Artery Bypass Graft (CABG) patients. While compression therapy, like compressive stockings, has benefits in preventing edema, concerns about affordability persist. CPG-EB provides optimal sub-bandage pressure, proven effective in venous leg ulcers. Implementing CPG-EB post-CABG could enhance venous blood flow, reducing complications and improving outcomes. Patients were divided into two groups: one with CPG-EB and the other standard post-CABG care. Data collected at 1, 2, and 6 weeks post-surgery assessed swelling and wound complications. Comparative analysis used standardized criteria.",[257,258,259,260,261,262,263,264,265,266,267],"Limb Edema","Surgical Site Infections","Leg Swelling","Compression Bandages","Coronary Artery Bypass Graft","CABG","Saphenectomy","Saphenous Vein","Delayed Wound Healing","Post Operative Complications","Post Operative Surgical Site Infection",[269,270,271,262,272],"compression bandages","compression therapy","customized pressure-guided elastic bandages","coronary arterial bypass graft","2026-02-06",{"date":275,"type":32},"2026-02-09",{"date":277,"type":32},"2025-01-19",{"date":279,"type":20},"2026-05-31",{"name":38,"class":39},2,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":51,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":4},"100623888","phase-2-a-phase-ii-prospective-study-of-maastro-applicator-brachytherapy-for-rectal-cancer-100623888","NCT07402486","A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer","A Phase II Prospective Clinical Study to Evaluate the Feasibility, Safety, and Early Efficacy of Maastro Applicator High-Dose-Rate Brachytherapy in Selected Patients With Rectal Cancer","Inclusion Criteria:\n\nAge ≥ 18 years at the time of informed consent Histologically confirmed rectal cancer Any T, N, or M stage, provided the primary rectal lesion is suitable for endorectal HDR brachytherapy Tumor characteristics deemed suitable for treatment with the Maastro applicator (per investigator assessment) Rectal lesion accessible for applicator placement and adequate visualization Adequate organ function to undergo sedation\u002Fanesthesia and brachytherapy, as judged by the investigator Ability to comply with study procedures, imaging, and scheduled follow-up Written informed consent obtained prior to study participation\n\nExclusion Criteria:\n\nActive inflammatory bowel disease with moderate to severe disease activity Uncontrolled proctitis not attributable to tumor involvement Severe anorectal conditions that preclude safe applicator placement (e.g., severe anal stenosis, uncontrolled hemorrhoidal bleeding, severe radiation-induced proctopathy in the target area) Any medical, psychiatric, or social condition that, in the opinion of the investigator, would interfere with safe study participation or interpretation of results",{"count":290,"type":20},20,[137],"Rectal cancer is a common type of cancer and an important cause of illness and death worldwide. In 2020, cancers of the colon and rectum were the fourth most common cancers globally, and about one third of these cases were rectal cancer. Surgery is the main treatment for rectal cancer. In more advanced cases, chemotherapy and external beam radiotherapy are often given before surgery. However, surgery can sometimes result in a permanent stoma (an opening on the abdomen for bowel movements) and carries higher risks of complications, especially in older patients or those with other medical problems. Because of this, there is growing interest in treatment approaches that can control the cancer while avoiding major surgery when possible.\n\nSome studies suggest that in carefully selected patients, rectal cancer can be treated without removing the rectum if the tumor responds well to radiation and chemotherapy. In these patients, survival outcomes may be similar to those who undergo surgery, although the risk of the cancer growing back locally can be slightly higher. This means that careful and long-term follow-up is very important. One of the key challenges with non-surgical treatment is determining how much radiation is needed to completely eliminate the tumor while minimizing side effects.\n\nContact X-ray brachytherapy is a type of radiation treatment that delivers a high dose of radiation directly to the tumor using low-energy X-rays. Because the radiation is given very close to the tumor, it can better target the cancer while reducing radiation exposure to surrounding healthy tissues. This technique has been used in Europe for many years and is recommended by international guidelines in selected patients, mainly within research settings. Other forms of brachytherapy using modern radiation sources can achieve similar dose distributions and may also support organ-preserving treatment strategies.\n\nA new medical device called the Maastro applicator has been developed for use with high-dose-rate (HDR) brachytherapy systems. This applicator is designed to deliver radiation in a way that closely mimics low-energy X-ray treatments, while being compatible with widely available HDR brachytherapy equipment. Early technical studies suggest that it can deliver radiation accurately and safely, but its clinical effectiveness and safety in patients with rectal cancer have not yet been fully studied.\n\nThis phase II prospective study aims to evaluate the feasibility, safety, and early treatment outcomes of using the Maastro applicator for brachytherapy in patients with rectal cancer. The study will assess how often the tumor completely disappears after treatment, how well the cancer is controlled over time, the side effects of treatment, and how patients' quality of life changes. The results of this study will help determine whether this treatment approach is suitable for wider clinical use and will contribute to improving future treatment options for patients with rectal cancer.",[294],"Rectal Cancer",[296,297,298,299],"HDR brachytherapy","Ractal cancer","Contact brachytherapy","MAASTRO applicator","2026-02-04",{"date":302,"type":32},"2026-02-11",{"date":304,"type":20},"2026-03-01",{"date":306,"type":20},"2027-12-31",{"name":38,"class":39},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":226,"enrollmentInfo":314,"targetDuration":4,"studyType":51,"phases":316,"briefSummary":317,"conditions":318,"keywords":323,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":40},"100620986","phase-2-protective-effect-of-acetylcysteine-against-cisplatinum-induced-ototoxicity-a-randomized-controlled-trial-100620986","NCT07364747","Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged between 18 and 70 years\n* Patients scheduled to receive high-dose cisplatin-based chemotherapy regimens with a projected cumulative cisplatin dose of \\> 200 mg\u002Fm2 and each dose \\> 50 mg\u002Fm2\n* Patients may receive concurrent chemotherapy with non-ototoxic agents\n* Patients may receive concurrent radiation therapy to the skull base, provided the radiation dose does not exceed the toxic threshold for ototoxicity\n* Patients receiving an appropriate antiemetic regimen consisting of Olanzapine or Neurokinin-1 (NK1) receptor antagonists\n* Patients receiving medical treatment at Siriraj Hospital.\n\nExclusion Criteria:\n\n* Patients diagnosed with Nasopharyngeal Carcinoma (CA nasopharynx).\n* Patients with a history of head and neck radiation therapy where the radiation dose to the cochlea exceeded 9 Gy or the dose to the eustachian tube exceeded 50 Gy on both sides.\n* Patients who have received N-acetylcysteine (NAC) within 2 weeks prior to the start of the study.\n* Patients who have received other ototoxic drugs within 2 weeks prior to or during the study, including but not limited to:\n\nAminoglycoside antibiotics, Vancomycin, Loop diuretics (e.g., Furosemide), High-dose Aspirin, Antimalarial drugs (e.g., Quinine)\n\n\\- Patient with a known allergy or hypersensitivity to acetylcysteine.",{"count":315,"type":20},40,[137],"The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy. Cisplatin is a highly effective chemotherapeutic agent but often leads to permanent hearing loss (ototoxicity) as a significant side effect. This study investigates whether the administration of NAC as an otoprotective agent can reduce or prevent the decline in hearing sensitivity, particularly at extended high frequencies, as measured by audiometry and distortion product otoacoustic emissions (DPOAE).",[319,320,321,322],"Cisplatin-induced Ototoxicity","Sensorineural Hearing Loss","Ototoxicity","Ototoxicity, Drug-Induced",[319,320,321],"2026-01-16",{"date":326,"type":32},"2026-01-23",{"date":328,"type":32},"2024-12-23",{"date":330,"type":20},"2027-03-31",{"name":38,"class":39},{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":51,"phases":342,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":40},"100532832","early-intravenous-hydrocortisone-in-sepsis-100532832","NCT06217939","Early Intravenous Hydrocortisone in Sepsis","Early Intravenous Hydrocortisone in Sepsis: a Randomized Control Trial","EARL-HYDRO","Inclusion Criteria:\n\n* Age of 18 years or older\n* Suspected or definite sepsis Sepsis is defined by SEPSIS-3 definition as Sequential Organ Failure Assessment (SOFA) score ≥ 2 from baseline with suspected infection.2 Suspected sepsis is defined as patients with suspected infection who meet 2 or more criteria of quick SOFA (altered mentation, respiratory rate ≥ 22\u002Fmin, systolic blood pressure ≤ 100 mmHg).\n* Hypotension (mean arterial pressure \\< 65 mmHg)\n\nExclusion Criteria:\n\n* Randomization and administration of the study drugs are not able to be executed within 3 hours after the onset of hypotension\n* Causes of shock other than sepsis identified\n* Immunocompromised A patient is considered immunocompromised if one of the following criteria is met: history of human immunodeficiency virus infection or acquired immunodeficiency syndrome, hematologic malignancy, receiving chemotherapy, active cancer receiving chemotherapy, current use of immunosuppressive medication)\n* Hyperglycemic crisis (diabetic ketoacidosis, hyperosmolar hyperglycemic state)\n* Pregnancy\n* Post-cardiac arrest\n* Received etomidate before randomization\n* Systemic corticosteroids indicated for other conditions\n* Received systemic corticosteroids within 4 weeks at any dose\n* Cancer patients who are receiving palliative treatment\n* Do-not-resuscitate order",{"count":341,"type":20},230,[53],"The goal of this clinical trial is to compare two timings of steroid treatment in patients with severe infection who develop low blood pressure.\n\nThe main question it aims to answer is:\n\n• Which timing strategy is better between starting steroid treatment very early in the course of severe infection, or waiting until the patient does not respond to medicine that raises blood pressure according to the current guidelines?\n\nParticipants will receive either early steroid treatment or placebo right after they develop low blood pressure from infection. Both participants and treating doctors will not know which treatment participants received. When blood pressure goal is not reached after a moderate dose of drugs that raise blood pressure, an open-label steroid treatment will be given to participants as indicated in the current guidelines.",[345,346],"Sepsis Severe","Shock, Septic",[117,348,349,350],"hydrocortisone","shock","early","2026-01-05",{"date":353,"type":32},"2026-01-07",{"date":355,"type":32},"2024-06-25",{"date":357,"type":20},"2026-09",{"name":38,"class":39},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":51,"phases":367,"briefSummary":368,"conditions":369,"keywords":375,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":40},"100531715","the-efficacy-of-p01-guided-sedation-protocol-in-critically-ill-patients-receiving-invasive-mechanical-ventilation-a-randomized-controlled-trial-100531715","NCT06203405","The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients admitted to the medical intensive care unit at Department of Medicine, Siriraj Hospital\n2. Age ≥18 years old\n3. Receiving mechanical ventilation due to acute respiratory failure within 72 hours before enrollment (including patients receiving mechanical ventilation before ICU admission)\n\nExclusion Criteria:\n\n1. Patients receiving mechanical ventilation due to indications other than acute respiratory failure, such as postoperative procedures or airway protection in comatose patients\n2. Patients receiving mechanical ventilation for \\>72 hours before enrollment\n3. Patients receiving neuromuscular blocking agents prior to randomization\n4. Patients with impaired secretion clearance or upper airway obstruction anticipating a tracheostomy\n5. Patients with severe metabolic acidosis (arterial pH \\\u003C7.2) who do not have a plan for renal replacement therapy\n6. Patients intubated for neurological conditions, including intracranial hypertension, intracranial hemorrhage, large cerebral infarction, status epilepticus, or neuromuscular diseases\n7. Post-cardiac arrest patients\n8. Patients with severe liver dysfunction, including acute fulminant liver failure or cirrhosis with the Child-Pugh score B or C\n9. Patients who have a previous allergy to any of the opioid, sedation, or neuromuscular blocking drugs\n10. Pregnancy\n11. Patients with do-not-resuscitate (DNR) orders or decisions to withhold life-sustaining treatments\n12. Patients who refuse to participate in the study or cannot identify legally authorized representatives (LAR) within 24 hours after enrollment",{"count":366,"type":20},214,[53],"This clinical trial aims to assess the efficacy of sedation protocol targeting optimal respiratory drive using P0.1 and arousal level compared with conventional sedation strategy (targeting arousal level alone) in patients requiring mechanical ventilation in the medical intensive care unit.",[370,371,372,373,374],"Respiratory Failure","Critical Illness","Respiratory Distress Syndrome, Adult","Lung Injury","Mechanical Ventilation Complication",[376,377,378,379,380],"acute respiratory failure","sedation","respiratory drive monitoring","mechanical ventilation","intensive care unit","2025-05-19",{"date":383,"type":32},"2025-05-22",{"date":385,"type":32},"2023-12-22",{"date":387,"type":20},"2026-06-30",{"name":38,"class":39},{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":225,"sex":16,"minAge":17,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":281},"100568711","prevalence-and-characteristics-of-restless-leg-syndrome-in-thai-patients-with-parkinsons-disease-100568711","NCT06684782","Prevalence and Characteristics of Restless Leg Syndrome in Thai Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Patients with Parkinson's disease aged from 18 to 80 years who met the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Diagnostic criteria.\n\nExclusion Criteria:\n\n* Patients with atypical or secondary parkinsonism.\n* Patients with Mini-mental status exam (MMSE) less than 24 of 30.\n* Patients with secondary causes of restless leg syndrome including end-stage renal disease, iron deficiency anemia and pregnancy.","80 Years",{"count":397,"type":20},310,"Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by pathologic intraneuronal alpha-synuclein-positive Lewy bodies and neuronal cell loss. The cardinal clinical symptoms and signs of PD are bradykinesia, rigidity, tremor, postural instability, and freezing attacks. The prevalence of PD increases with age, affecting 1-2% of the population over the age of 65 years, and 3% of those over 85 years.\n\nRestless legs syndrome (RLS) represents disturbing symptoms in lower limbs that lead to the urge to move, occurring in rest periods. Movements can partially or completely relieve these abnormal feelings. In 2014, the International RLS Study Group (IRLSSG) established five mandatory criteria for the diagnosis of RLS. Several studies supported that RLS and PD may share pathophysiological mechanisms.",[400],"Restless Legs Syndrome",[234,402,403,404],"parkinson's disease","prevalence","Thai population","2025-05-12",{"date":407,"type":32},"2025-05-15",{"date":409,"type":32},"2024-12-01",{"date":411,"type":20},"2026-11-30",{"name":38,"class":39},{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":225,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":40},"100588881","the-role-of-angiographic-measurements-and-anatomical-correlations-in-intra-aortic-balloon-pump-iabp-size-selection-100588881","NCT06947174","The Role of Angiographic Measurements and Anatomical Correlations in Intra-Aortic Balloon Pump (IABP) Size Selection","Inclusion Criteria:\n\n* Patients had obtained CT scan of chest with upper abdomen with celiac trunk visualize within 1 year from the day of transfemoral angiography\n* Patients had who will undergo transfemoral angiography as clinical indicated\n* Patients had obtained Chest X-ray within 1 year from the day of transfemoral angiography\n\nExclusion Criteria:\n\n* Patient with limb amputation\n* Patient with known aortic abnormalities such as aortic aneurysm, aortic dissection",{"count":420,"type":20},68,"The goal of this study aim to accurately size the IABP size for patients. The main questions it aims to answer are:\n\n* Are patients's height, jugular notch to transpyloric plane distance and distance from the carina to the upper part of the first lumbar vertebra (measured by chest X-ray) are a good surrogate for IABP sizing?\n* Is the distance obtained during a transfemoral artery catheterization a reliable way to size the IABP? Researchers will enroll patient who have had previous CT that include thoracic aorta to celiac trunk who will undergo transfemoral angiography.\n* All patients that researcher enrolled will undergo transfemoral angiography, during which the researchers will measure the vessel distance using a wire after the procedure end.\n* Researchers will measure the height weight, jugular notch to transpyloric plane distance, CXR distance from carina to upper border of L1 and the distance from aorta at subclavian level to celiac trunk from CT.\n* Researchers will find the correlation between of each measurement to the distance from aorta at subclavian level to celiac trunk from CT (considered the standard measure).",[423],"Intra-aortic Balloon Pump",[425],"Intra-aortic balloon pump","2025-04-19",{"date":428,"type":32},"2025-04-27",{"date":430,"type":32},"2025-01-25",{"date":432,"type":20},"2025-12-31",{"name":38,"class":39},{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":441,"targetDuration":4,"studyType":51,"phases":443,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":40},"100576466","phase-4-budesonide-irrigation-in-allergic-rhinitis-100576466","NCT06785662","Budesonide Irrigation in Allergic Rhinitis","The Efficacy of Budesonide Nasal Irrigation in Allergic Rhinitis Patients: A Randomized, Controlled Trial.","Inclusion Criteria:\n\n* Participants aged 18-60 years diagnosed with perennial allergic rhinitis based on ARIA guidelines, who have previously consistently used intranasal corticosteroids for at least 2 weeks with inadequate control of nasal inflammation defined by a VAS score of ≥5 out of 10 and requiring dosage adjustment. Noted that proper technique should have been confirmed through retrospective questioning.\n\nExclusion Criteria:\n\n* Those with a history of sinus surgery, nasal or sinus tumors (including polyps), significant deviated nasal septum causing symptoms, oral corticosteroid uses for any indication, immunodeficiency, pregnancy, breastfeeding, or suspected fungal sinusitis indicated by ischemic nasal tissue, fungal masses, bone erosion, or calcifications on imaging were excluded. Participants would be withdrawn if severe complications arise from the use of topical budesonide.",{"count":442,"type":20},78,[444],"PHASE4","Topical nasal steroids are significant therapeutic options for allergic rhinitis (AR). The distribution of intranasal steroid spray (INS) administration is less than that of irrigation. However, the available data on steroid nasal irrigation is limited. This article aims to evaluate the efficacy and adverse effects (AEs) of steroid irrigation in AR patients.",[447],"Allergic Rhinitis",[449,450,451,452],"intranasal corticosteroid","budesonide nasal irrigation","Budesonide nasal spray","Allergic rhinitis","2025-01-20",{"date":455,"type":32},"2025-01-21",{"date":457,"type":20},"2025-02-12",{"date":459,"type":20},"2026-06-01",{"name":38,"class":39},{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":51,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":40},"100573026","phase-3-long-term-efficacy-of-once-daily-versus-twice-daily-aspirin-in-high-risk-mpn-patients-with-aspirin-resistance-100573026","NCT06740916","Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance","Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk Myeloproliferative Neoplasms Patients With Aspirin Resistance","Inclusion Criteria:\n\n* Philadelphia negative Myeloproliferative neoplasms aged at least 18 years old\n\nExclusion Criteria:\n\n* Concomitant other active malignancy or cured less than 6 months\n* Platelet count less than 50,000\u002FmicroL\n* Receiving anticoagulant\n* Active peptic ulcer\n* Active bleeding or Planning to undergo procedure\u002Foperation with bleeding risk\n* No laboratory aspirin resistance with LTA method",{"count":469,"type":20},240,[138],"Patients with myeloproliferative neoplasm (MPN) could have laboratory aspirin resistance and then increasing dose of aspirin from once daily to twice daily regimen is suggested. However, it is not routinely recommended to perform platelet function testing to determine aspirin resistance in MPN patients. Moreover, it is not known whether increasing dose of aspirin would always correct aspirin resistance and significantly prevent the thrombotic events in MPN patients. Therefore, this study aims to compare the efficacy of once daily versus twice daily aspirin in high-risk MPN patients with aspirin resistance. MPN patients with laboratory aspirin resistance will be included in this prospective randomized study and platelet function testing will be repeated at one and six months later. Clinical thrombosis and side effect from aspirin will be recorded for at least 2 years after intervention.",[473],"Myeloproliferative Neoplasms (MPN)",[475,476],"myeloproliferative neoplasm","aspirin resistance",{"date":478,"type":32},"2024-12-27",{"date":480,"type":32},"2024-12-12",{"date":482,"type":20},"2030-12-31",{"name":38,"class":39},{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100541517","disease-characteristics-and-treatment-response-in-plasma-cell-disorders-patients-based-on-genetic-abnormalities-from-fluorescence-in-situ-hybridization-and-next-generation-sequencing-100541517","NCT06330896","Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing","genetics MM","Inclusion Criteria:\n\n* Patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis\n* Aged 18 years and older\n* Performed FISH and\u002For NGS testing\n* Has treatment follow up at least one year\n\nExclusion Criteria:\n\n* Patients with missing crucial data that renders them unanalyzable\n* Patients who refuse to participate in the study",{"count":492,"type":20},498,"The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are:\n\n* genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and\u002For NGS testing\n* genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients.\n* disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and\u002For genetic mutations detected by NGS.\n* correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients.\n\nThe FISH and\u002For NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and\u002For NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.",[495],"Plasma Cell Disorder",[495,497,498,499,500,501],"genetic abnormalities","Fluorescence In Situ Hybridization","FISH","Next Generation Sequencing","NGS","2024-03-19",{"date":504,"type":32},"2024-03-26",{"date":506,"type":20},"2024-04-01",{"date":508,"type":20},"2028-04-01",{"name":38,"class":39},{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":517,"targetDuration":519,"studyType":21,"phases":4,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100538084","registry-of-haploidentical-hematopoietic-stem-cell-transplantation-in-adult-with-hematologic-disease-100538084","NCT06286228","Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease","Haplo","Inclusion Criteria:\n\n* Patients diagnosed with hematologic diseases indicated for treatment with haploidentical hematopoietic stem cell transplantation including\n\n  1. Myeloid diseases (acute myeloblastic leukemia, myelodysplastic syndrome, chronic myelocytic leukemia, classical and non-classical myeloproliferative disorders)\n  2. Lymphoid disease (acute lymphoblastic leukemia, lymphoma)\n  3. severe aplastic anemia\n* Unable to find a matched sibling donor (MSD) or matched unrelated donor (MUD), and no alternative treatments\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* normal AST and ALT, creatinine \\<2g\u002FdL, and left ventricular ejection fraction ≥50%\n* age \\>18 years\n* Capable of informed consent and provision of written informed consent before any study procedures\n* Capable of attending all study visits according to the study schedule\n* Female subjects who is childbearing potential must have a negative result for pregnancy test\n\nExclusion Criteria:\n\n* HIV infection, active hepatitis B, active hepatitis C\n* active infection\n* history of other malignancy except basal cell carcinoma and carcinoma of the cervix in situ\n* A pregnant woman and\u002For refusal of contraception",{"count":518,"type":20},43,"5 Years","The goal of this observational study is to register hematologic patients with haploidentical hematopoietic stem cell transplantation (haploHSCT). The main questions it aims to answer are:\n\n* 1-year progression free survival rate\n* 1-year overall survival rate\n* Graft-versus-host free relapsed free survival at 30-day, 100-day, 180-day and 1-year\n* Chronic Graft-versus-host free relapsed free survival at 180-day and 1-year\n* Rate of Neutrophil and platelet engraftment\n* Efficacy of donor specific antibody desensitization\n* Relapsed rate\n* Primary and late graft failure\n* Safety and complication of haploHSCT\n* Complication of viral, bacterial, and fungal infection\n* Viral reactivation\n* Comparison outcomes between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT\n* Comparison cost-effectiveness of treatment between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.",[522],"Multiple Myeloma",[524,525],"haploidentical hematopoietic stem cell transplantation (haploHSCT)","registry","2024-02-28",{"date":528,"type":32},"2024-03-01",{"date":506,"type":20},{"date":531,"type":20},"2030-04-01",{"name":38,"class":39},{"id":534,"slug":535,"hasResults":11,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":540,"targetDuration":542,"studyType":21,"phases":4,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":552,"leadSponsor":554,"locationsCount":4},"100538083","registry-of-patients-with-plasma-cell-disorders-100538083","NCT06286215","Registry of Patients With Plasma Cell Disorders","Registry PCD","Inclusion Criteria:\n\n* Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014\n* Aged 18 years and above\n\nExclusion Criteria:\n\n* insufficient data needed for analysis",{"count":541,"type":20},750,"10 Years","The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:\n\n* The incidence of plasma cell disorders both before and after malignancy\n* Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)\n* Progression free survival (PFS)\n* overall survival\n* factors influencing overall survival, progression-free survival, and time to progression\n* Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients.\n* genetic characteristics of plasma cell disorder\n* cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.",[545],"Plasma Cell Disorders",[525,547],"plasma cell disorder","2024-02-22",{"date":550,"type":32},"2024-02-29",{"date":506,"type":20},{"date":553,"type":20},"2035-04-01",{"name":38,"class":39},""]